Quarterly ResultMay 7, 2026, 08:33 AM
Silence Therapeutics Q1 Net Loss $(14.96)M, Revenue $0.42M
AI Summary
Silence Therapeutics plc reported a significant reduction in net loss for the first quarter of 2026, narrowing to $(14.96) million from $(28.53) million in the prior year. Revenue also saw an increase to $0.42 million. Despite these improvements, the company continues to incur operating losses and will require additional funding for its clinical development activities, although it believes current cash is sufficient into 2028.
Key Highlights
- Net loss significantly narrowed to $(14.96) million for Q1 2026 from $(28.53) million in Q1 2025.
- Revenue increased to $0.42 million for Q1 2026, up from $0.14 million in Q1 2025.
- Operating loss improved to $(15.74) million for Q1 2026 compared to $(28.41) million in Q1 2025.
- Research and development costs decreased to $(9.12) million in Q1 2026 from $(20.81) million in Q1 2025.
- Loss per share improved to $(0.11) for Q1 2026 from $(0.20) in Q1 2025.
- Cash and cash equivalents and short-term investments totaled $70.1 million as of March 31, 2026.
- Company believes current cash and equivalents are sufficient to fund operations into 2028.
Price Impact
More from SLN